linjc16/ctgov huggingface dataset:
Risk for Short-term Adverse Events in Older Emergency Department Users

Study Overview
=================
Brief Summary
-----------------
This study evaluates the association between risk levels (i.e.; low, moderate and high) of Emergency Room Tool (ER2) and length of stay in older Emergency Room Tool (ER) users admitted to the medical or surgery wards of the Jewish General Hospital.

Detailed Description
-----------------
The Emergency Room Tool (ER2) assessment can be used by Emergency Department nurses taking care of older Emergency Department (ED) users on stretcher, and that ER2 moderate and high risk levels is associated with long length of stay in Emergency Department and hospital as well as hospital admissions.

Official Title
-----------------
Risk for Short-term Adverse Events in Older Emergency Department Users: '' Emergency Room Evaluation and Recommendation '' Cohort Study Database

Conditions
-----------------
Older People, Health Care, Evaluations, Health Impairment

Intervention / Treatment
-----------------
* Other: Emergency Room Evaluation Tool (ER2)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being 75 years and over An unplanned Emergency Department visit and to be on a stretcher. Exclusion Criteria: -Being 74 years and less

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Emergency Room Evaluation Tool (ER2)<br>Patients who are 75 years and over, and who are brought to Emergency in stretchers will be evaluated based on the Emergency Room Evaluation Tool (ER2). | Other: Emergency Room Evaluation Tool (ER2)<br>* Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short-term adverse events | By using the Emergency Room Evaluation Tool( ER2), we will indirectly evaluate the length of hospital stay. The calculation will be done in days and hours. | In around 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability of assessment tool | Patients at Emergency Room will be valuated by using the Emergency Room Evaluation Tool(ER2). Based on the ER2 results, it would be evaluated the usability of the Emergency Room screening tool. | 24 hours in Emergency |
Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to evaluate the effect of treatment with darbepoetin alfa on peak oxygen consumption (peak VO2) in subjects with symptomatic CHF and anemia.

Official Title
-----------------
A Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Conditions
-----------------
Congestive Heart Failure, Anemia

Intervention / Treatment
-----------------
* Drug: darbepoetin alfa


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Symptomatic CHF for at least 3 months - Reduced left ventricular ejection fraction - Stable heart failure medication - Peak VO2 less than or equal to 16 ml/kg/min - Hemoglobin concentration between 9.0 and 12.0 g/dL Exclusion Criteria: - Hypertension - Unstable angina pectoris or recent myocardial infarction - Likely to receive cardiac transplant - Unable to do cardiopulmonary exercise testing - Major organ transplant (e.g., lung, liver, heart) or renal replacement therapy (e.g., dialysis) - Recent or current treatment for malignancy - Systemic hematologic disease - Anemia due to acute or chronic bleeding - Recent Epogen® or darbepoetin alfa therapy - Recent blood transfusion

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: darbepoetin alfa|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise tolerance, measured as peak VO(subscript)2 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise duration; *NYHA classification; *Patient-reported outcomes |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anemia, chronic heart failure, congestive heart failure, low hemoglobin, CHF, Symptomatic Congestive Heart Failure (CHF)
Circulating Endothelial Progenitor Cells and Aortic Aneurysm

Study Overview
=================
Brief Summary
-----------------
We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Detailed Description
-----------------
Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm >30mm and <50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Official Title
-----------------
Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm

Conditions
-----------------
- Aortic Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aortic aneurysm size >30mm and > 50mm Exclusion Criteria: Infectious disease Inflammatory disease Liver insuffisency Cancer evolutive Pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Aortic aneurysm<br>Patients with aortic aneurysm >30mm and < 50mm | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration | Patients are followed for 2 years | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aortic aneurysm, circulating endothelial progenitor cells
Marital Functioning Among Combat Veterans

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to examine marital dynamics related to husband-wife reunification following the veteran's return

Detailed Description
-----------------
We are interested in patterns of husband/wife communication and interaction regarding conflict resolution, trauma experiences, marital satisfaction, occupational functioning, social functioning, family functioning, and substance use. We hope to discover ways to assist couples in reducing marital stress.

Official Title
-----------------
Marital Functioning Among Combat Veterans

Conditions
-----------------
Stress Disorders, Post-Traumatic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 and older Married or in a married like relationship One partner has served in Afghanistan or Iraq Exclusion Criteria: Separated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to obtain lymphocyte collections from normal healthy volunteer donors in order to create Good Manufacturing Practice grade banks of virus-specific and tumor-reactive T-cells of defined HLA type and restricting HLA allele readily available for therapeutic use.

Official Title
-----------------
Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Leukapheresis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Donors must satisfy standards including those set forth by FACT (Foundation for the Accreditation of Cellular Therapy) and the criteria specified in FDA 21 Code of Federal Regulations (CFR) 1271. Specifically, screening for risk factors for communicable disease as well as infectious disease screening by serologic and PCR testing as outlined below. Including testing for IV, Hepatitis B, Hepatitis C, HTLV I and II, CMV, EBV, and toxoplasmosis, westnile virus, syphilis, varicella zoster, and Chagas disease. Donors must be typed for HLA-A, B, C, DR and DQ at high resolution. Donors accrued at MSKCC must have a hemoglobin value > 10g/dl Donors must be capable of undergoing, at least, a single standard 2 blood volume leukapheresis or a donation of one unit of whole blood Donors must weight >/= 25 kg Exclusion Criteria: HTLV/HIV (+) or Hepatitis B or C positive donors Donors who are pregnant
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Consenting healthy donor<br>Transplant and healthy HLA typed donors | Other: Leukapheresis<br>* Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Generation of T-cells | Blood and/or white cell donations will be used for the generation of the T-cells to be used for adoptive immunotherapy. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transplant donor, HLA typed, 17-211
Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals

Study Overview
=================
Brief Summary
-----------------
Impaired uptake of glucose by skeletal muscle is a key feature of type 2 diabetes mellitus. It is unclear to what extent impaired insulin uptake from capillaries into skeletal muscle interstitium plays a role in this process. We hypothesize that impaired uptake of insulin from capillaries into skeletal muscle interstitium is involved in impaired glucose uptake by skeletal muscle in type 2 diabetes mellitus.

Official Title
-----------------
Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals

Conditions
-----------------
Type 2 Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria for all participants: written informed consent hemodynamically stable with a systolic blood pressure > 100 mmHg medical need to undergo a CAG procedure as determined by cardiologist Exclusion criteria for all participants: ongoing myocardial infarction as determined from elevated cardiac markers participation in an investigational trial within 90 days prior to present study donation of blood (> 100 mL) within 90 days prior to present study serious mental impairment or language problems i.e. preventing to understand the study protocol/aim Use or recent use (within 3 months of study participation) of oral glucocorticoids Inclusion criteria for non-diabetic individuals: 30 years ≤ age ≤ 80 years (extremes included) fasting glucose level of < 7.0 mmol/L and HbA1C < 6.5% (= < 48 mmol/mol) Exclusion criteria for non-diabetic individuals: - known T2DM/use of glucose-lowering medication Inclusion criteria for T2DM patients: 30 years ≤ age ≤ 80 years (extremes included) fasting glucose level of > 7.0 mmol/L, or HbA1C > 6.5 (= > 48 mmol/mol) or known T2DM Exclusion criteria for T2DM patients: - treatment with insulin preparations

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with type 2 diabetes mellitus<br> | |
| Normoglycemic individuals<br>Control group | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fore-arm insulin uptake measured as ([A]-[V]) x F in pmol/min where A = arterial insulin concentrations, V= venous insulin concentrations, F = fore arm plasma flow; | During a single measure (thus cross-sectional) the primary endpoint will be measured. | Baseline |
Exercise-training Before Coronary Artery Bypass Graft (CABG)

Study Overview
=================
Brief Summary
-----------------
The aim is to evaluate the effect of exercise training upon endothelial function in the mammary artery of patients who are scheduled for CABG, as well as study the functional properties of single cells isolated from a small biopsy of the left ventricle obtained during surgery.

Official Title
-----------------
Exercise-training Before Coronary Artery Bypass Graft (CABG)

Conditions
-----------------
Angina, Coronary Artery Disease

Intervention / Treatment
-----------------
* Behavioral: Exercise training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Scheduled for CABG both with and without heart failure Exclusion Criteria: Unstable angina Unable to walk on a treadmill (except those with heart failure who only will serve as a reference group) Participation in another study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: exercise training<br> | Behavioral: Exercise training<br>* Intensity controlled exercise training before the scheduled bypass surgery<br>|
| No Intervention: physician's advice<br>patients follow their physician's advice in regard to physical activity. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular function and quality of life |  | Before and up to 1 year after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Structure and function of cardiomyocytes |  | After the intervention period | 
| Cardiomyocyte structure and function |  | after the intervention period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aerobic capacity, Exercise training, CABG, Endothelial function
Effect of Prednisolone Treatment on Uterine Natural Killer Cells

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the role of uNK cells and the association with prednisolone.

Detailed Description
-----------------
Glucocorticoids prednisolone is considered as a potential therapy in women with recurrent miscarriage. However, the evidence for treatment with prednisolone is still inconclusive and the relevant mechanism merits further investigations. The participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.

Official Title
-----------------
Effect of Prednisolone Treatment on Uterine Natural Killer Cells and Endometrial Angiogenesis in Recurrent Miscarriage Around the Time of Embryo Implantation

Conditions
-----------------
Recurrent Miscarriage

Intervention / Treatment
-----------------
* Drug: Prednisolone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with a history of 3 or more consecutive miscarriages Women younger than 40 years old Exclusion Criteria: Allergy to prednisolone Women who have any uterine anomaly Antiphospholipid syndrome Hydrosalpinx Thrombophilia Abnormal thyroid function tests women with diabetes,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: The participants will be invited to take prednisolone oral 10 mg/day and attend our outpaitent clinic to be performed endometrial biopsy.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: prednisolone<br>prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH plus 7. Women will be then given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days. | Drug: Prednisolone<br>* prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the number of uNK cells | to investigate the association between uNK cells and prednisolone | at the 1 day of endometrial biopsy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
recurrent miscarriage, prednisolone treatment
Comparative Study Between Cryoablation and Radiofrequency Ablation in the Treatment of Supraventricular Tachycardia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the safety and effectiveness of cryoablation and radiofrequency ablation in the treatment of the commonest kind of supraventricular tachycardia, namely atrioventricular nodal reentrant tachycardia. The study hypothesis is that cryoablation is non-inferior to radiofrequency.

Official Title
-----------------
CRYOthermy and Radiofrequency ABLation For AVNRT TrEatment

Conditions
-----------------
Supraventricular Tachycardia, Atrioventricular Nodal Reentrant Tachycardia

Intervention / Treatment
-----------------
* Procedure: cryoablation
* Procedure: radiofrequency ablation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are referred for catheter ablation of supraventricular tachycardia and diagnosis of AVNRT is made by cardiac electrophysiology study Exclusion Criteria: Patients who aged less than 18 or over 80. Patients who are pregnant. Patients who cannot give informed consent. Patients who are judged to have severe mental impairment and cannot report symptoms of palpitation during follow-up. Patients who had previous AVNRT ablation before. Patients who have comorbid congenital heart disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cryoablation<br> | Procedure: cryoablation<br>* cryoablation with an 8mm-tip catheter<br>|
| Active Comparator: radiofrequency ablation<br>radiofrequency ablation with a 4mm-tip catheter | Procedure: radiofrequency ablation<br>* radiofrequency ablation with a 4mm-tip catheter<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment success rate, defined as proportion of treated patients with both atrioventricular block-free acute procedural success and mid-term success without recurrence at 6 months |  | 6 months after treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment success rate at 12 months |  | 12 months after treatment |